National Cancer Institute
Found 670 results for your search:
Total relevant funding to Melanoma for this search:
$153,176,356
Fiscal Year FY 2017
Cancer Type [Melanoma]
Modify this Search New Search
Close

Modify Search Criteria

Some search criteria may be modified to refine your current search.

Select criteria to modify:

Add or remove search options:

Select criteria above to see additional search options

Cancel
Showing 1 - 50 of 670 results
Clipboard
Project Title Sorted ascending Project Number Funded Amount
Relevant Funding
Principal
Investigator
Institution
1
(6) Molecular mechanisms explaining premalignant changes in the etiology of melanoma 1R21CA208736-01A1 $146,000 $146,000 MURPH, MANDI UNIVERSITY OF GEORGIA
2
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration 1R01CA205965-01A1 $650,815 $650,815 CURIEL, TYLER UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
3
(PQ3) The role of damaged DNA in inter-individual variation of tumor immunity 5R01CA208756-02 $518,165 $259,083 HACOHEN, NIR BROAD INSTITUTE, INC.
4
(PQB-4) Opposing Effects of the SASP in Cancer Progression 5R01CA184572-04 $329,925 $112,175 HERBIG, UTZ RBHS-NEW JERSEY MEDICAL SCHOOL
5
(PQD1) Clonal heterogeneity and targeted therapy resistance in melanoma 5R01CA185072-04 $348,312 $348,312 SEKULIC, ALEKSANDAR MAYO CLINIC ARIZONA
6
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells 5R01CA185151-04 $613,546 $613,546 NOVINA, CARL DANA-FARBER CANCER INST
7
(PQD5) Mass Profiling Melanoma Responses to Improve Therapy Choices and Prognosis 5R01CA185189-04 $483,693 $483,693 TEITELL, MICHAEL UNIVERSITY OF CALIFORNIA LOS ANGELES
8
(PQD5) Predicting Anti-Cancer Efficacy through Tumor Profiling 5R01CA185353-04 $405,890 $405,890 KIM, WILLIAM UNIV OF NORTH CAROLINA CHAPEL HILL
9
0021.0001 CG 425 METAVIVOR 261200800001E $319,219,481 $141,683 UNKNOWN, UNKNOWN LEIDOS BIOMEDICAL RESEARCH, INC.
10
1/2 SDSU/UCSD Cancer Center Comprehensive Partnership 5U54CA132379-08 $1,258,708 $188,806 MARTINEZ, MARIA UNIVERSITY OF CALIFORNIA SAN DIEGO
11
2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership 2U54CA163068-06 $1,656,304 $182,193 MUNOZ-ANTONIA, TERESITA H. LEE MOFFITT CANCER CTR & RES INST
12
3D Models of Immunotherapy 1U01CA214369-01 $574,412 $574,412 MOONEY, DAVID HARVARD UNIVERSITY
13
A CD47-blocking oncolytic vaccinia virus for cancer therapy 5F30CA203270-02 $44,044 $44,044 CAO, FELICIA BAYLOR COLLEGE OF MEDICINE
14
A comparison of interventions to teach patients skin self-examination 5R01CA154908-07 $593,036 $593,036 ROBINSON, JUNE NORTHWESTERN UNIVERSITY AT CHICAGO
15
A germline variant that predicts and modulates the response of melanoma to immunotherapy 1R21CA209309-01A1 $198,103 $198,103 OSMAN, IMAN NEW YORK UNIVERSITY SCHOOL OF MEDICINE
16
A High-Throughput Model for Human Melanoma 5R01CA121118-09 $247,340 $247,340 HOLMEN, SHERI UNIVERSITY OF UTAH
17
A NOVEL DRUGGABLE GENETIC VULNERABILITY PATHWAY IN MELANOMA 5R01CA200919-02 $383,156 $383,156 WAJAPEYEE, NARENDRA YALE UNIVERSITY
18
A novel IL-2 biologic and tumor immunity 5R21CA195334-02 $200,318 $200,318 MALEK, THOMAS UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
19
A novel in vivo model system of melanoma using a human-mouse neural crest cell chimera 5F32CA196065-03 $59,166 $59,166 WERT, KATHERINE WHITEHEAD INSTITUTE FOR BIOMEDICAL RES
20
A novel NKG2D-specific BiTE cancer immunotherapy 5R01CA164178-05 $336,150 $168,075 SENTMAN, CHARLES DARTMOUTH COLLEGE
21
A novel preclinical model of spontaneous metastasis ZIA BC 011167 $524,680 $498,446 Merlino, Glenn CCR (NCI)
22
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma 1R44CA217591-01 $621,000 $621,000 KAHN, STUART SYNTRIX BIOSYSTEMS, INC.
23
A real-time, cost-effective, accurate UV measurement and sun protection system to prevent and reduce the incidence of sunburn in high-risk consumers. 1R44CA224658-01 $213,796 $213,796 Meitl, Matthew WEARIFI, INC.
24
A research and training program for junior clinicians in treating metastatic mela 5K24CA172123-05 $156,084 $156,084 KLUGER, HARRIET YALE UNIVERSITY
25
A role for AKT2 in BRAFV600E melanoma initiation, progression, and response to therapy 5F31CA210312-02 $39,784 $39,784 MCREE, SIOBHAN TUFTS UNIVERSITY BOSTON
26
A Self-Regulation Approach to an Indoor Tanning Intervention for Frequent Users 5K07CA175115-04 $137,183 $137,183 STAPLETON, JEROD RBHS -CANCER INSTITUTE OF NEW JERSEY
27
Abramson Cancer Center Support Grant 3P30CA016520-41S1 $125,000 $6,250 DANG, CHI UNIVERSITY OF PENNSYLVANIA
28
Abramson Cancer Center Support Grant 3P30CA016520-41S2 $62,491 $3,125 VONDERHEIDE, ROBERT UNIVERSITY OF PENNSYLVANIA
29
Abramson Cancer Center Support Grant 5P30CA016520-41 $7,810,244 $390,512 VONDERHEIDE, ROBERT UNIVERSITY OF PENNSYLVANIA
30
Adaptive regulation of cancer cell fate following oncogene inhibition 4R00CA194163-03 $249,001 $249,001 FALLAHI-SICHANI, MOHAMMAD UNIVERSITY OF MICHIGAN
31
Adoptive Cell Therapy with Rejuvenated Antigen-Specific T Cells 5K08CA197966-04 $174,960 $174,960 ITO, FUMITO ROSWELL PARK CANCER INSTITUTE CORP
32
Adoptive Cell Transfer Immunotherapy of Cancer ZIA BC 010984 $1,629,581 $1,466,623 Rosenberg, Steven CCR (NCI)
33
Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research 5U24CA180921-05 $705,863 $141,173 BECICH, MICHAEL UNIVERSITY OF PITTSBURGH AT PITTSBURGH
34
An innate immune checkpoint in cancer immunotherapy 1R01CA212376-01A1 $455,406 $455,406 ROTHLIN, CARLA YALE UNIVERSITY
35
An integrated translational approach to overcome drug resistance 1U54CA224068-01 $2,500,407 $825,134 CORCORAN, RYAN MASSACHUSETTS GENERAL HOSPITAL
36
An Internet-Based Behavioral Intervention for Individuals Diagnosed with Melanoma 5R01CA171666-04 $492,128 $492,128 COUPS, ELLIOT RBHS -CANCER INSTITUTE OF NEW JERSEY
37
Anatomic Pathology Residency Program ZIE BC 011384 $1,094,457 $43,778 Barr, Frederic CCR (NCI)
38
Animal Model and Genotyping Core Support Facility ZIC BC 011047 $814,201 $244,260 DuBois, Wendy CCR (NCI)
39
Anti-CD38 targeted alpha emitter radioimmunotherapy to eliminate multiple myeloma 1R01CA205248-01A1 $697,579 $697,579 GREEN, DAMIAN FRED HUTCHINSON CANCER RESEARCH CENTER
40
Antibodies to melanoma vaccine peptides 1R03CA219715-01 $80,500 $80,500 SLINGLUFF, CRAIG UNIVERSITY OF VIRGINIA
41
Antigen-specific T-cell Activation, Application to Vaccines for Cancer and AID ZIA SC 004020 $2,592,300 $388,845 Berzofsky, Jay CCR (NCI)
42
Area C: Genome-wide identification and targeting of resistance to cancer therapy 1R33CA225291-01 $1,459,166 $364,792 RUPPIN, EYTAN UNIV OF MARYLAND, COLLEGE PARK
43
Assessing the effect of anti-PD-1/PD-L1 agents on tumoricidal efficacy of secretory TRAIL-armed NK cells 1R03CA205267-01A1 $77,312 $77,312 LEE, YONG UNIVERSITY OF PITTSBURGH AT PITTSBURGH
44
Assisted Network-based Analysis of Cancer Gene Expression Studies 1R03CA216017-01 $83,750 $27,638 MA, SHUANGGE YALE UNIVERSITY
45
Augmenting T cell activity to weak tumor antigens and reversing myeloid cell-mediated T cell inhibition 1R01CA207913-01A1 $363,833 $363,833 DAVILA, EDUARDO UNIVERSITY OF MARYLAND BALTIMORE
46
Automated Image Guidance for Diagnosing Skin Cancer With Confocal Microscopy 5R01CA199673-03 $619,539 $619,539 RAJADHYAKSHA, MILIND SLOAN-KETTERING INST CAN RESEARCH
47
Automated Platform for Fixed Tissue Microdissection 4R44CA199194-02 $747,594 $747,594 KARSTEN, STANISLAV NEUROINDX INC.
48
b-catenin in vaccine-induced anti-tumor CD8 T cell immunity 5R01CA198105-03 $401,456 $200,728 JIANG, AIMIN ROSWELL PARK CANCER INSTITUTE CORP
49
BACH2 in Melanoma Development and Resistance 5K22CA197058-02 $177,344 $177,344 KARRETH, FLORIAN H. LEE MOFFITT CANCER CTR & RES INST
50
Basic and Preclinical Animal Models in support of Cancer and HIV-AIDS Research ZIG BC 010856 $14,497,944 $724,898 Custer, Mary CCR (NCI)
Total relevant funding to Melanoma for this search: $153,176,356
Showing 1 - 50 of 670 results
Go to top